Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. The company's mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm. Landos has a portfolio of novel targets anchoring two libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space. The company is currently focused on advancing the clinical development of NX-13 in UC. Landos initiated its NEXUS Phase 2 proof-of-concept trial in April 2023 and expects to report topline results by the fourth quarter of 2024.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.